ID   CEBPB_RAT               Reviewed;         297 AA.
AC   P21272; A2VD03;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   02-OCT-2024, entry version 191.
DE   RecName: Full=CCAAT/enhancer-binding protein beta {ECO:0000312|RGD:2327};
DE            Short=C/EBP beta {ECO:0000312|RGD:2327};
DE   AltName: Full=C/EBP-related protein 2;
DE   AltName: Full=Interleukin-6-dependent-binding protein;
DE            Short=IL-6DBP;
DE   AltName: Full=Liver-enriched inhibitory protein;
DE            Short=LIP;
DE   AltName: Full=Liver-enriched transcriptional activator;
DE            Short=LAP;
DE   AltName: Full=Silencer factor B;
DE            Short=SF-B;
GN   Name=Cebpb {ECO:0000312|RGD:2327};
GN   Synonyms=Crp2, Nf-il6 {ECO:0000303|PubMed:8336793}, Sfb;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2171780; DOI=10.1016/0092-8674(90)90459-r;
RA   Poli V., Mancini F.P., Cortese R.;
RT   "IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction,
RT   defines a new family of leucine zipper proteins related to C/EBP.";
RL   Cell 63:643-653(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Lewis; TISSUE=Liver;
RX   PubMed=2253878; DOI=10.1101/gad.4.9.1541;
RA   Descombes P., Chojkier M., Lichtsteiner S., Falvey E., Schibler U.;
RT   "LAP, a novel member of the C/EBP gene family, encodes a liver-enriched
RT   transcriptional activator protein.";
RL   Genes Dev. 4:1541-1551(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND SUBUNIT.
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=1377818; DOI=10.1093/nar/20.12.3091;
RA   Thomassin H., Hamel D., Bernier D., Guertin M., Belanger L.;
RT   "Molecular cloning of two C/EBP-related proteins that bind to the promoter
RT   and the enhancer of the alpha 1-fetoprotein gene. Further analysis of C/EBP
RT   beta and C/EBP gamma.";
RL   Nucleic Acids Res. 20:3091-3098(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 77-297 (ISOFORM 1).
RC   TISSUE=Liver;
RA   Imagawa M., Osada S., Koyama Y., Suzuki T., Hirom P.C., Diccianni M.B.,
RA   Morimura S., Muramatsu M.;
RT   "SF-B (Silencer Factor B) that binds to a negative element in glutathione
RT   transferase P gene is most likely identical to an inducible trans-activator
RT   LAP/IL6-DBP.";
RL   Submitted (JUL-1991) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-297, SUBUNIT, AND DNA-BINDING.
RC   STRAIN=Sprague-Dawley; TISSUE=Adipose tissue, Liver, and Lung;
RX   PubMed=1884998; DOI=10.1101/gad.5.9.1553;
RA   Williams S.C., Cantwell C.A., Johnson P.F.;
RT   "A family of C/EBP-related proteins capable of forming covalently linked
RT   leucine zipper dimers in vitro.";
RL   Genes Dev. 5:1553-1567(1991).
RN   [7]
RP   FUNCTION, ALTERNATIVE SPLICING (ISOFORMS 1; 2 AND 3), DNA-BINDING,
RP   DIMERIZATION, AND SUBUNIT.
RX   PubMed=1934061; DOI=10.1016/0092-8674(91)90531-3;
RA   Descombes P., Schibler U.;
RT   "A liver-enriched transcriptional activator protein, LAP, and a
RT   transcriptional inhibitory protein, LIP, are translated from the same
RT   mRNA.";
RL   Cell 67:569-579(1991).
RN   [8]
RP   FUNCTION, PHOSPHORYLATION AT SER-105, AND MUTAGENESIS OF SER-105.
RX   PubMed=8336793; DOI=10.1038/364544a0;
RA   Trautwein C., Caelles C., van der Geer P., Hunter T., Karin M.,
RA   Chojkier M.;
RT   "Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its
RT   activation domain.";
RL   Nature 364:544-547(1993).
RN   [9]
RP   FUNCTION, PHOSPHORYLATION AT SER-105, MUTAGENESIS OF SER-105, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=10635333; DOI=10.1016/s1097-2765(00)80237-3;
RA   Buck M., Poli V., van der Geer P., Chojkier M., Hunter T.;
RT   "Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBP beta is
RT   required for hepatocyte proliferation induced by TGF alpha.";
RL   Mol. Cell 4:1087-1092(1999).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH NFE2L1.
RX   PubMed=15308669; DOI=10.1074/jbc.m405031200;
RA   Narayanan K., Ramachandran A., Peterson M.C., Hao J., Kolstoe A.B.,
RA   Friedman A.D., George A.;
RT   "The CCAAT enhancer-binding protein (C/EBP)beta and Nrf1 interact to
RT   regulate dentin sialophosphoprotein (DSPP) gene expression during
RT   odontoblast differentiation.";
RL   J. Biol. Chem. 279:45423-45432(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Important transcription factor regulating the expression of
CC       genes involved in immune and inflammatory responses (PubMed:8336793).
CC       Also plays a significant role in adipogenesis, as well as in the
CC       gluconeogenic pathway, liver regeneration, and hematopoiesis
CC       (PubMed:10635333). The consensus recognition site is 5'-
CC       T[TG]NNGNAA[TG]-3'. Its functional capacity is governed by protein
CC       interactions and post-translational protein modifications. During early
CC       embryogenesis, plays essential and redundant roles with CEBPA (By
CC       similarity). Has a promitotic effect on many cell types such as
CC       hepatocytes and adipocytes but has an antiproliferative effect on T-
CC       cells by repressing MYC expression, facilitating differentiation along
CC       the T-helper 2 lineage (PubMed:10635333). Binds to regulatory regions
CC       of several acute-phase and cytokines genes and plays a role in the
CC       regulation of acute-phase reaction and inflammation. Also plays a role
CC       in intracellular bacteria killing (By similarity). During adipogenesis,
CC       is rapidly expressed and, after activation by phosphorylation, induces
CC       CEBPA and PPARG, which turn on the series of adipocyte genes that give
CC       rise to the adipocyte phenotype. The delayed transactivation of the
CC       CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic
CC       clonal expansion and thereby progression of terminal differentiation
CC       (By similarity). Essential for female reproduction because of a
CC       critical role in ovarian follicle development (By similarity).
CC       Restricts osteoclastogenesis: together with NFE2L1; represses
CC       expression of DSPP during odontoblast differentiation
CC       (PubMed:15308669). {ECO:0000250|UniProtKB:P17676,
CC       ECO:0000250|UniProtKB:P28033, ECO:0000269|PubMed:10635333,
CC       ECO:0000269|PubMed:15308669, ECO:0000269|PubMed:1934061,
CC       ECO:0000269|PubMed:8336793}.
CC   -!- FUNCTION: [Isoform 2]: Essential for gene expression induction in
CC       activated macrophages. Plays a major role in immune responses such as
CC       CD4(+) T-cell response, granuloma formation and endotoxin shock. Not
CC       essential for intracellular bacteria killing.
CC       {ECO:0000250|UniProtKB:P28033}.
CC   -!- FUNCTION: [Isoform 3]: Acts as a dominant negative through
CC       heterodimerization with isoform 2 (PubMed:1934061). Promotes osteoblast
CC       differentiation and osteoclastogenesis (By similarity).
CC       {ECO:0000250|UniProtKB:P17676, ECO:0000250|UniProtKB:P28033,
CC       ECO:0000269|PubMed:1934061}.
CC   -!- SUBUNIT: Binds DNA as a homodimer and as a heterodimer
CC       (PubMed:1934061). Interacts with MYB; within the complex, MYB and CEBPB
CC       bind to different promoter regions. Interacts with ATF4. Binds DNA as a
CC       heterodimer with ATF4 (By similarity). Can form stable heterodimers
CC       with CEBPA, CEBPD, CEBPE and CEBPG (PubMed:1377818, PubMed:1884998).
CC       Interacts with SIX1 (By similarity). Isoform 2 and isoform 3 also form
CC       heterodimers (PubMed:1934061). Interacts with TRIM28 and PTGES2.
CC       Interacts with PRDM16. Interacts with CCDC85B. Forms a complex with
CC       THOC5. Interacts with ZNF638; this interaction increases
CC       transcriptional activation. Interacts with CIDEA and CIDEC; these
CC       interactions increase transcriptional activation of a subset of CEBPB
CC       downstream target genes. Interacts with DDIT3/CHOP.Interacts with
CC       EP300; recruits EP300 to chromatin. Interacts with RORA; the
CC       interaction disrupts interaction with EP300. Interacts (not methylated)
CC       with MED23, MED26, SMARCA2, SMARCB1 and SMARCC1 (By similarity).
CC       Interacts with KAT2A and KAT2B (By similarity). Interacts with ATF5;
CC       EP300 is required for ATF5 and CEBPB interaction and DNA binding (By
CC       similarity). Interacts with NFE2L1; the heterodimer represses
CC       expression of DSPP during odontoblast differentiation
CC       (PubMed:15308669). {ECO:0000250|UniProtKB:P17676,
CC       ECO:0000250|UniProtKB:P28033, ECO:0000269|PubMed:1377818,
CC       ECO:0000269|PubMed:15308669, ECO:0000269|PubMed:1884998,
CC       ECO:0000269|PubMed:1934061}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P17676}. Cytoplasm
CC       {ECO:0000250|UniProtKB:P17676}. Note=Translocates to the nucleus when
CC       phosphorylated at Ser-288. In T-cells when sumoylated drawn to
CC       pericentric heterochromatin thereby allowing proliferation (By
CC       similarity). {ECO:0000250|UniProtKB:P17676,
CC       ECO:0000250|UniProtKB:P28033}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=3;
CC       Name=1; Synonyms=FL;
CC         IsoId=P21272-1; Sequence=Displayed;
CC       Name=2; Synonyms=LAP;
CC         IsoId=P21272-2; Sequence=VSP_053316;
CC       Name=3; Synonyms=LIP;
CC         IsoId=P21272-3; Sequence=VSP_053315;
CC   -!- TISSUE SPECIFICITY: Liver and lung.
CC   -!- PTM: Phosphorylated at Thr-189 by MAPK and CDK2, serves to prime
CC       phosphorylation at Thr-180 and Ser-185 by GSK3B and acquire DNA-binding
CC       as well as transactivation activities, required to induce adipogenesis.
CC       MAPK and CDK2 act sequentially to maintain Thr-189 in the primed
CC       phosphorylated state during mitotical cloning expansion and thereby
CC       progression of terminal differentiation (By similarity).
CC       Phosphorylation at Ser-105 enhances transactivation activity
CC       (PubMed:8336793). Phosphorylation at Ser-277 in response to calcium
CC       increases transactivation activity. Phosphorylated at Thr-189 by
CC       RPS6KA1 (By similarity). {ECO:0000250|UniProtKB:P17676,
CC       ECO:0000250|UniProtKB:P28033, ECO:0000269|PubMed:8336793}.
CC   -!- PTM: Methylated. Methylation at Arg-3 by CARM1 and at Lys-39 by EHMT2
CC       inhibit transactivation activity. Methylation is probably inhibited by
CC       phosphorylation at Thr-189. {ECO:0000250|UniProtKB:P17676}.
CC   -!- PTM: Sumoylated by polymeric chains of SUMO2 or SUMO3 (By similarity).
CC       Sumoylation at Lys-134 is required for inhibition of T-cells
CC       proliferation. In adipocytes, sumoylation at Lys-134 by PIAS1 leads to
CC       ubiquitination and subsequent proteasomal degradation. Desumoylated by
CC       SENP2, which abolishes ubiquitination and stabilizes protein levels (By
CC       similarity). {ECO:0000250|UniProtKB:P17676,
CC       ECO:0000250|UniProtKB:P28033}.
CC   -!- PTM: Ubiquitinated, leading to proteasomal degradation.
CC       {ECO:0000250|UniProtKB:P28033}.
CC   -!- PTM: O-glycosylated, glycosylation at Ser-181 and Ser-182 prevents
CC       phosphorylation on Thr-189, Ser-185 and Thr-180 and DNA binding
CC       activity which delays the adipocyte differentiation program.
CC       {ECO:0000250|UniProtKB:P28033}.
CC   -!- PTM: Acetylated. Acetylation at Lys-39 is an important and dynamic
CC       regulatory event that contributes to its ability to transactivate
CC       target genes, including those associated with adipogenesis and
CC       adipocyte function. Deacetylation by HDAC1 represses its
CC       transactivation activity. Acetylated by KAT2A and KAT2B within a
CC       cluster of lysine residues between amino acids 99-103, this acetylation
CC       is strongly induced by glucocorticoid treatment and enhances
CC       transactivation activity. {ECO:0000250|UniProtKB:P28033}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Not detected in rat liver.
CC   -!- MISCELLANEOUS: [Isoform 2]: Major form in. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the bZIP family. C/EBP subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M57235; AAA19669.1; -; mRNA.
DR   EMBL; X54626; CAA38443.1; -; Genomic_DNA.
DR   EMBL; BC129071; AAI29072.1; -; mRNA.
DR   EMBL; X60769; CAA43179.1; -; mRNA.
DR   EMBL; AY056052; AAA40972.1; -; Genomic_DNA.
DR   PIR; A35914; A35914.
DR   RefSeq; NP_001288644.1; NM_001301715.1. [P21272-2]
DR   RefSeq; NP_001288649.1; NM_001301720.1. [P21272-3]
DR   RefSeq; NP_077039.3; NM_024125.5. [P21272-1]
DR   AlphaFoldDB; P21272; -.
DR   SMR; P21272; -.
DR   BioGRID; 246438; 1305.
DR   ComplexPortal; CPX-62; bZIP transcription factor complex, Cebpb-Ddit3.
DR   ComplexPortal; CPX-63; bZIP transcription factor complex, Cebpb-Cebpb.
DR   DIP; DIP-28139N; -.
DR   IntAct; P21272; 2.
DR   STRING; 10116.ENSRNOP00000071427; -.
DR   GlyCosmos; P21272; 2 sites, No reported glycans.
DR   GlyGen; P21272; 3 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P21272; -.
DR   PhosphoSitePlus; P21272; -.
DR   PaxDb; 10116-ENSRNOP00000065222; -.
DR   PeptideAtlas; P21272; -.
DR   GeneID; 24253; -.
DR   KEGG; rno:24253; -.
DR   UCSC; RGD:2327; rat. [P21272-1]
DR   AGR; RGD:2327; -.
DR   CTD; 1051; -.
DR   RGD; 2327; Cebpb.
DR   VEuPathDB; HostDB:ENSRNOG00000057347; -.
DR   eggNOG; KOG3119; Eukaryota.
DR   HOGENOM; CLU_043327_1_0_1; -.
DR   InParanoid; P21272; -.
DR   OrthoDB; 2959124at2759; -.
DR   PhylomeDB; P21272; -.
DR   TreeFam; TF105008; -.
DR   Reactome; R-RNO-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   PRO; PR:P21272; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   Bgee; ENSRNOG00000057347; Expressed in liver and 19 other cell types or tissues.
DR   GO; GO:1990647; C:C/EBP complex; ISO:RGD.
DR   GO; GO:0036488; C:CHOP-C/EBP complex; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0000785; C:chromatin; ISO:RGD.
DR   GO; GO:0000779; C:condensed chromosome, centromeric region; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0016363; C:nuclear matrix; IDA:RGD.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISO:RGD.
DR   GO; GO:0003682; F:chromatin binding; ISO:RGD.
DR   GO; GO:0031490; F:chromatin DNA binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISS:UniProtKB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:RGD.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; ISO:RGD.
DR   GO; GO:0042826; F:histone deacetylase binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0019900; F:kinase binding; ISO:RGD.
DR   GO; GO:0035259; F:nuclear glucocorticoid receptor binding; IPI:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISO:RGD.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISO:RGD.
DR   GO; GO:0044389; F:ubiquitin-like protein ligase binding; ISO:RGD.
DR   GO; GO:0050873; P:brown fat cell differentiation; ISO:RGD.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; ISO:RGD.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IDA:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:RGD.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:UniProtKB.
DR   GO; GO:0001892; P:embryonic placenta development; ISO:RGD.
DR   GO; GO:0045444; P:fat cell differentiation; ISO:RGD.
DR   GO; GO:0002432; P:granuloma formation; ISS:UniProtKB.
DR   GO; GO:0072574; P:hepatocyte proliferation; IDA:UniProtKB.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; ISO:RGD.
DR   GO; GO:0001889; P:liver development; IEP:RGD.
DR   GO; GO:0097421; P:liver regeneration; ISS:UniProtKB.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; ISO:RGD.
DR   GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISO:RGD.
DR   GO; GO:0007613; P:memory; IEP:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISO:RGD.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; ISO:RGD.
DR   GO; GO:0001541; P:ovarian follicle development; ISS:UniProtKB.
DR   GO; GO:0070169; P:positive regulation of biomineral tissue development; ISO:RGD.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISO:RGD.
DR   GO; GO:2000120; P:positive regulation of sodium-dependent phosphate transport; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0045595; P:regulation of cell differentiation; IBA:GO_Central.
DR   GO; GO:2001198; P:regulation of dendritic cell differentiation; ISO:RGD.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0032675; P:regulation of interleukin-6 production; ISO:RGD.
DR   GO; GO:1901329; P:regulation of odontoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0045670; P:regulation of osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISO:RGD.
DR   GO; GO:0035711; P:T-helper 1 cell activation; ISS:UniProtKB.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISO:RGD.
DR   CDD; cd14712; bZIP_CEBPB; 1.
DR   Gene3D; 1.20.5.170; -; 1.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR046347; bZIP_sf.
DR   InterPro; IPR031106; C/EBP.
DR   InterPro; IPR016468; C/EBP_chordates.
DR   PANTHER; PTHR23334; CCAAT/ENHANCER BINDING PROTEIN; 1.
DR   PANTHER; PTHR23334:SF21; CCAAT_ENHANCER-BINDING PROTEIN BETA; 1.
DR   Pfam; PF07716; bZIP_2; 1.
DR   PIRSF; PIRSF005879; CCAAT/enhancer-binding; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   SUPFAM; SSF57959; Leucine zipper domain; 1.
DR   PROSITE; PS50217; BZIP; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Alternative initiation; Cytoplasm; Differentiation;
KW   DNA-binding; Glycoprotein; Isopeptide bond; Methylation; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..297
FT                   /note="CCAAT/enhancer-binding protein beta"
FT                   /id="PRO_0000076619"
FT   DOMAIN          223..286
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          1..22
FT                   /note="Required for Lys-134 sumoylation"
FT                   /evidence="ECO:0000250|UniProtKB:P17676"
FT   REGION          22..105
FT                   /note="Required for MYC transcriptional repression"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   REGION          172..201
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          227..247
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          249..256
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   COMPBIAS        172..190
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         3
FT                   /note="Asymmetric dimethylarginine; by CARM1"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   MOD_RES         39
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   MOD_RES         39
FT                   /note="N6-methylated lysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   MOD_RES         99
FT                   /note="N6-acetyllysine; by KAT2A and KAT2B"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   MOD_RES         102
FT                   /note="N6-acetyllysine; by KAT2A and KAT2B"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   MOD_RES         103
FT                   /note="N6-acetyllysine; by KAT2A and KAT2B; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   MOD_RES         105
FT                   /note="Phosphoserine; by RPS6KA1 and PKC/PRKCA"
FT                   /evidence="ECO:0000269|PubMed:10635333,
FT                   ECO:0000269|PubMed:8336793"
FT   MOD_RES         180
FT                   /note="Phosphothreonine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   MOD_RES         185
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   MOD_RES         189
FT                   /note="Phosphothreonine; by RPS6KA1, CDK2 and MAPK"
FT                   /evidence="ECO:0000250|UniProtKB:P17676"
FT   MOD_RES         240
FT                   /note="Phosphoserine; by PKC/PRKCA"
FT                   /evidence="ECO:0000250|UniProtKB:P17676"
FT   MOD_RES         277
FT                   /note="Phosphoserine; by CaMK2"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   CARBOHYD        181
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   CARBOHYD        182
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250|UniProtKB:P28033"
FT   CROSSLNK        103
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P17676"
FT   CROSSLNK        134
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P17676,
FT                   ECO:0000250|UniProtKB:P28033"
FT   CROSSLNK        134
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P17676"
FT   CROSSLNK        145
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P17676"
FT   CROSSLNK        212
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P17676"
FT   CROSSLNK        214
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P17676"
FT   CROSSLNK        284
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P17676"
FT   VAR_SEQ         1..152
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053315"
FT   VAR_SEQ         1..21
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053316"
FT   MUTAGEN         105
FT                   /note="S->A: No effect on DNA-binding. Loss of
FT                   transactivation activity. Loss of hepatocyte proliferation
FT                   induction by TGFA."
FT                   /evidence="ECO:0000269|PubMed:10635333,
FT                   ECO:0000269|PubMed:8336793"
FT   MUTAGEN         105
FT                   /note="S->D: No effect on DNA-binding. Increases
FT                   transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:8336793"
SQ   SEQUENCE   297 AA;  31503 MW;  C2511FDB65527789 CRC64;
     MHRLLAWDAA CLPPPPAAFR PMEVANFYYE PDCLAYGAKA ARAAPRAPAA EPAIGEHERA
     IDFSPYLEPL APAAADFAAP APAHHDFLSD LFADDYGAKP SKKPSDYGYV SLGRAGAKAA
     PPACFPPPPP AALKAEPGFE PADCKRADDA PAMAAGFPFA LRAYLGYQAT PSGSSGSLST
     SSSSSPPGTP SPADAKAAPA ACFAGPPAAP AKAKAKKAVD KLSDEYKMRR ERNNIAVRKS
     RDKAKMRNLE TQHKVLELTA ENERLQKKVE QLSRELSTLR NLFKQLPEPL LASAGHC
//
